Third-generation FLT3 inhibitors in clinical development

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/56/f2/b8/56f2b88c-f71b-11ca-2fa0-ecddc1044fe8/mza_2145894122309428224.jpg/600x600bb.jpg

MediCom Oncology Clinical Pearls Podcasts

MediCom Oncology

53 episodes

1 month ago

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

RSS

All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.

Science

https://i1.sndcdn.com/artworks-000428812299-vyyozs-t3000x3000.jpg

Third-generation FLT3 inhibitors in clinical development

MediCom Oncology Clinical Pearls Podcasts

2 minutes 42 seconds

7 years ago

Third-generation FLT3 inhibitors in clinical development

Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.